实用癌症杂志
實用癌癥雜誌
실용암증잡지
THE PRACTICAL JOURNAL OF CANCER
2014年
2期
123-125
,共3页
毛建华%罗庆丰%刘志礼%王恒%朱粮博%龙新华%周荣平
毛建華%囉慶豐%劉誌禮%王恆%硃糧博%龍新華%週榮平
모건화%라경봉%류지례%왕항%주량박%룡신화%주영평
LY294002%成骨肉瘤%侵袭迁徙
LY294002%成骨肉瘤%侵襲遷徙
LY294002%성골육류%침습천사
LY294002%Osteosarcoma%Invasion and migration
目的:探讨LY294002对成骨肉瘤细胞体外侵袭迁徙的影响。方法不同浓度的LY294002作用U2-OS细胞24 h,检测细胞增殖情况;Wound healing 和Transwell invasion 实验检测细胞迁徙和侵袭情况。结果 LY294002可抑制U2-OS细胞增殖并呈剂量依赖;LY294002(40μM)处理细胞组细胞迁徙率为(37.97±2.49)%,阴性对照组细胞迁徙率为(83.78±2.84)%,两组间具有显著的统计学差异( P<0.01);LY294002(40μM)处理细胞组穿膜细胞数显著低于阴性对照组穿膜细胞数〔分别为(36.1±5.0)个/视野和(89.1±6.4)个/视野〕( P<0.01)。结论 LY294002能有效抑制成骨肉瘤细胞U2-OS细胞体外迁徙,有望成为成骨肉瘤化学治疗药物。
目的:探討LY294002對成骨肉瘤細胞體外侵襲遷徙的影響。方法不同濃度的LY294002作用U2-OS細胞24 h,檢測細胞增殖情況;Wound healing 和Transwell invasion 實驗檢測細胞遷徙和侵襲情況。結果 LY294002可抑製U2-OS細胞增殖併呈劑量依賴;LY294002(40μM)處理細胞組細胞遷徙率為(37.97±2.49)%,陰性對照組細胞遷徙率為(83.78±2.84)%,兩組間具有顯著的統計學差異( P<0.01);LY294002(40μM)處理細胞組穿膜細胞數顯著低于陰性對照組穿膜細胞數〔分彆為(36.1±5.0)箇/視野和(89.1±6.4)箇/視野〕( P<0.01)。結論 LY294002能有效抑製成骨肉瘤細胞U2-OS細胞體外遷徙,有望成為成骨肉瘤化學治療藥物。
목적:탐토LY294002대성골육류세포체외침습천사적영향。방법불동농도적LY294002작용U2-OS세포24 h,검측세포증식정황;Wound healing 화Transwell invasion 실험검측세포천사화침습정황。결과 LY294002가억제U2-OS세포증식병정제량의뢰;LY294002(40μM)처리세포조세포천사솔위(37.97±2.49)%,음성대조조세포천사솔위(83.78±2.84)%,량조간구유현저적통계학차이( P<0.01);LY294002(40μM)처리세포조천막세포수현저저우음성대조조천막세포수〔분별위(36.1±5.0)개/시야화(89.1±6.4)개/시야〕( P<0.01)。결론 LY294002능유효억제성골육류세포U2-OS세포체외천사,유망성위성골육류화학치료약물。
Objective Objective To investigate the effect of LY 294002 on invasion and migration in vitro of osteosarco-ma cells.Methods Various concentrations of LY294002 were adopted to deal with human osteosarcoma cells U 2-OS for 24 h;The cell proliferation was detected by MTT assay;Wound healing and Transwell invasion assays were performed to evaluate the cell migration and invasion abilities .Results The LY294002 could inhibite U2-OS cell proliferation dramatically and the inhibi-tory effect was concentration-dependent .The cell migration rates in LY294002 management group and the negative group were (37.9 ±2.49)%and (83.78 ±2.84)%,respectively.There was statistical difference .The trans-membraned cells in LY294002 management group were significantly lower than those of the negative group (36.1 ±5.0/HP and 89.1 ±6.4/HP,respectively) (P<0.01).Conclusion LY294002 could efficiently inhibit migration and invasion in vitro of osteosarcoma cells U 2-OS,and it has the potential to become a molecular target for anti-osteosarcoma metastasis .